Here, we report results of a randomised Phase II trial (NCT03659136) that evaluated the addition of xentuzumab to everolimus and exemestane in patients with HR-positive/HER2-negative advanced breast cancer with non-visceral disease who had received prior endocrine therapy with or without CDK4/6 inhibitors. Here, CDK4 is linked to breast cancer.